CHARACTERISTICS OF THE SCREENED STUDY POPULATION IN THE PREVENT-ADPKD TRIAL

ATY WONG1, C MANNIX1, J ZHANG1, DCH HARRIS1,2, VW LEE1,2, K SUD2,3, C WOOLNOUGH4 GK RANGAN1,2,3 ON BEHALF OF THE PREVENT-ADPKD TRIAL GROUP.

1Centre for Transplant and Renal Research, Westmead Institute for Medical Research, University of Sydney, Sydney, NSW; 2Department of Renal Medicine, Westmead Hospital, Western Sydney Local Health District, Sydney, NSW; 3Nepean Clinical School, Department of Renal Medicine, Nepean Hospital, University of Sydney, Sydney, NSW; 4Chemical Pathology, Royal Prince Alfred Hospital, Camperdown, NSW

Aim: To describe the characteristics of adults with autosomal dominant kidney disease (ADPKD) screened in the PREVENT-ADPKD trial.

Background: PREVENT-ADPKD is an investigator-initiated, multi-centre, parallel group randomised controlled trial designed to determine the efficacy of water intake prescribed to reduce urine osmolality to <270 mosmol/kg and systemic levels of vasopressin to prevent the progression of height-adjusted total kidney volume (ht-TKV) in ADPKD.

Methods: Adults (18-65yrs) diagnosed with ADPKD with CKD-EPI eGFR ≥30 mL/min/1.73m2 and able to complete magnetic resonance imaging (MRI) were included. Data from the first 50% of intended recruitment target (n=90) were analysed.

Results: The mean±SD age, gender, BMI, serum creatinine and eGFR of the cohort was 43±11 yrs, M:F 53:47%, 26±7 kg/m2, 95±32 µmol/L and 75±17 ml/min/1.73m2 respectively. The mean ht-TKV was 806±530 ml/m with the distribution of estimated annual TKV growth rate categories of <1.5%/yr (1A), 1.5-3.0%/yr (1B), 3-4.5%/yr (1C), 4.5-6%/yr (1D) and >6%/yr (1E) being 11.7, 23.3, 29.9, 27.2 and 7.8% respectively. The mean blood pressure (BP) was 133+82 mm Hg, and 13.6% had normal BP, 49% high-normal BP, 31% Grade 1 hypertension and 7% Grade 2 hypertension. Ht-TKV had a moderate correlation with log-transformed baseline serum copeptin (r=0.46, P<0.05) and serum creatinine (r=0.69, P<0.01) but by multi-variate analysis only the latter was a significant predictor. There were no baseline differences between gender except, height, serum creatinine and body weight which were all higher in men (P<0.05)

Conclusions: The screened population has similar characteristics to other clinical trial cohorts. Prognostic enrichment (exclusion of Mayo Subclass IA which constitute ~10% of screened population) will be used to select patients with a high-risk of progression.

About ANZSN

The ASM is hosted by Australian and New Zealand Society of Nephrology.

The aims of the Society are to promote and support the study of the kidney and urinary tract in health and disease, and to ensure the highest professional standards for the practice of nephrology in Australia and New Zealand.

Conference Managers

Please contact the team at Conference Design with any questions regarding the conference.
/wp-content/uploads/2017/08/Conference-Design-400x400.png
© 2015 - 2016 Conference Design Pty Ltd